27513357|t|Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators
27513357|a|Mesenchymal stromal cells are being investigated as a cell-based therapy for a number of disease processes, with promising results in animal models of systemic inflammation and sepsis. Studies are ongoing to determine ways to further improve the therapeutic potential of mesenchymal stromal cells. A gas molecule that improves outcome in experimental sepsis is carbon monoxide. We hypothesized that preconditioning of mesenchymal stromal cells with carbon monoxide ex vivo would promote further therapeutic benefit when cells are administered in vivo after the onset of polymicrobial sepsis in mice. Animal study and primary cell culture. Laboratory investigation. BALB/c mice. Polymicrobial sepsis was induced by cecal ligation and puncture. Mesenchymal stromal cells, mesenchymal stromal cells - conditioned with carbon monoxide, fibroblasts, or fibroblasts - conditioned with carbon monoxide were delivered by tail vein injections to septic mice. The mice were assessed for survival, bacterial clearance, and the inflammatory response during sepsis in each of the groups. Mesenchymal stromal cells were also assessed for their ability to promote bacterial phagocytosis by neutrophils, the production of specialized proresolving lipid mediators, and their importance for mesenchymal stromal cells function using gene silencing. Ex vivo preconditioning with carbon monoxide allowed mesenchymal stromal cells to be administered later after the onset of sepsis (6 hr), and yet maintain their therapeutic effect with increased survival. Carbon monoxide preconditioned mesenchymal stromal cells were also able to alleviate organ injury, improve bacterial clearance, and promote the resolution of inflammation. Mesenchymal stromal cells exposed to carbon monoxide, with docosahexaenoic acid substrate, produced specialized proresolving lipid mediators, particularly D-series resolvins, which promoted survival. Silencing of lipoxygenase pathways (5-lipoxygenase and 12 / 15-lipoxygenase), which are important enzymes for specialized proresolving lipid mediator biosynthesis, resulted in a loss of therapeutic benefit bestowed on mesenchymal stromal cells by carbon monoxide. Taken together, these data suggest that production of specialized proresolving lipid mediators contribute to improved mesenchymal stromal cell efficacy when exposed to carbon monoxide, resulting in an improved therapeutic response during sepsis.
27513357	0	15	Carbon Monoxide	T131,T197	C0007018
27513357	16	24	Improves	T033	C0184511
27513357	25	33	Efficacy	T080	C1280519
27513357	37	62	Mesenchymal Stromal Cells	T025	C3178844
27513357	63	69	During	T079	C0347984
27513357	70	76	Sepsis	T047	C0243026
27513357	94	105	Specialized	T077	C1704211
27513357	106	118	Proresolving	T033	C0243095
27513357	119	134	Lipid Mediators	T123	C0599745
27513357	135	160	Mesenchymal stromal cells	T025	C3178844
27513357	171	183	investigated	T169	C1292732
27513357	189	207	cell-based therapy	T061	C3658313
27513357	224	241	disease processes	T046	C0030660
27513357	258	265	results	T033	C2825142
27513357	269	282	animal models	T008	C0599779
27513357	286	307	systemic inflammation	T047	C3646020
27513357	312	318	sepsis	T047	C0243026
27513357	320	327	Studies	T062	C2603343
27513357	369	376	improve	T033	C0184511
27513357	381	392	therapeutic	T169	C0302350
27513357	393	402	potential	T080	C3245505
27513357	406	431	mesenchymal stromal cells	T025	C3178844
27513357	435	438	gas	T104	C0017110
27513357	439	447	molecule	T167	C0567416
27513357	453	461	improves	T033	C0184511
27513357	462	469	outcome	T169	C1274040
27513357	473	485	experimental	T080	C1517586
27513357	486	492	sepsis	T047	C0243026
27513357	496	511	carbon monoxide	T131,T197	C0007018
27513357	534	549	preconditioning	T169	C0205245
27513357	553	578	mesenchymal stromal cells	T025	C3178844
27513357	584	599	carbon monoxide	T131,T197	C0007018
27513357	600	607	ex vivo	T169	C2348480
27513357	614	621	promote	T052	C0033414
27513357	630	641	therapeutic	T169	C0302350
27513357	642	649	benefit	T081	C0814225
27513357	655	660	cells	T025	C0007634
27513357	665	677	administered	T169	C1521801
27513357	678	685	in vivo	T082	C1515655
27513357	696	704	onset of	T080	C0332162
27513357	705	718	polymicrobial	T047	C0275524
27513357	719	725	sepsis	T047	C0243026
27513357	729	733	mice	T015	C0025929
27513357	735	747	Animal study	T008	C0683949
27513357	752	772	primary cell culture	T059	C1449562
27513357	774	784	Laboratory	T073,T093	C0022877
27513357	785	798	investigation	T058	C0220825
27513357	800	811	BALB/c mice	T015	C0025919
27513357	813	826	Polymicrobial	T047	C0275524
27513357	827	833	sepsis	T047	C0243026
27513357	838	845	induced	T169	C0205263
27513357	849	854	cecal	T023	C0007531
27513357	855	863	ligation	T061	C0023690
27513357	868	876	puncture	T058	C0034117
27513357	878	903	Mesenchymal stromal cells	T025	C3178844
27513357	905	930	mesenchymal stromal cells	T025	C3178844
27513357	933	944	conditioned	T080	C0205556
27513357	950	965	carbon monoxide	T131,T197	C0007018
27513357	967	978	fibroblasts	T025	C0016030
27513357	983	994	fibroblasts	T025	C0016030
27513357	997	1008	conditioned	T080	C0205556
27513357	1014	1029	carbon monoxide	T131,T197	C0007018
27513357	1035	1044	delivered	T169	C1705822
27513357	1048	1057	tail vein	T023	C2985205
27513357	1058	1068	injections	T061	C1533685
27513357	1072	1078	septic	T169	C0333534
27513357	1079	1083	mice	T015	C0025929
27513357	1089	1093	mice	T015	C0025929
27513357	1099	1107	assessed	T052	C1516048
27513357	1112	1120	survival	T052	C0038952
27513357	1122	1131	bacterial	T080	C0521009
27513357	1132	1141	clearance	T080	C0449297
27513357	1151	1172	inflammatory response	T046	C1155266
27513357	1173	1179	during	T079	C0347984
27513357	1180	1186	sepsis	T047	C0243026
27513357	1202	1208	groups	T078	C0441833
27513357	1210	1235	Mesenchymal stromal cells	T025	C3178844
27513357	1246	1254	assessed	T052	C1516048
27513357	1265	1272	ability	T032	C0085732
27513357	1276	1283	promote	T052	C0033414
27513357	1284	1293	bacterial	T080	C0521009
27513357	1294	1306	phagocytosis	T043	C0031308
27513357	1310	1321	neutrophils	T025	C0027950
27513357	1341	1352	specialized	T077	C1704211
27513357	1353	1365	proresolving	T033	C0243095
27513357	1366	1381	lipid mediators	T123	C0599745
27513357	1408	1433	mesenchymal stromal cells	T025	C3178844
27513357	1434	1442	function	T039	C0031843
27513357	1449	1463	gene silencing	T045	C0598496
27513357	1465	1472	Ex vivo	T169	C2348480
27513357	1473	1488	preconditioning	T169	C0205245
27513357	1494	1509	carbon monoxide	T131,T197	C0007018
27513357	1518	1543	mesenchymal stromal cells	T025	C3178844
27513357	1550	1562	administered	T169	C1521801
27513357	1579	1587	onset of	T080	C0332162
27513357	1588	1594	sepsis	T047	C0243026
27513357	1626	1644	therapeutic effect	T201	C1527144
27513357	1650	1659	increased	T081	C0205217
27513357	1660	1668	survival	T052	C0038952
27513357	1670	1685	Carbon monoxide	T131,T197	C0007018
27513357	1686	1700	preconditioned	T081	C0205217
27513357	1701	1726	mesenchymal stromal cells	T025	C3178844
27513357	1755	1767	organ injury	T037	C0332675
27513357	1769	1776	improve	T033	C0184511
27513357	1777	1786	bacterial	T080	C0521009
27513357	1787	1796	clearance	T080	C0449297
27513357	1802	1809	promote	T052	C0033414
27513357	1814	1824	resolution	T046	C1514893
27513357	1828	1840	inflammation	T046	C0021368
27513357	1842	1867	Mesenchymal stromal cells	T025	C3178844
27513357	1868	1878	exposed to	T080	C0332157
27513357	1879	1894	carbon monoxide	T131,T197	C0007018
27513357	1901	1921	docosahexaenoic acid	T109,T121	C0556150
27513357	1922	1931	substrate	T167	C3891814
27513357	1942	1953	specialized	T077	C1704211
27513357	1954	1966	proresolving	T033	C0243095
27513357	1967	1982	lipid mediators	T123	C0599745
27513357	1997	2005	D-series	T080	C0205556
27513357	2006	2015	resolvins	T109	C4288292
27513357	2023	2031	promoted	T052	C0033414
27513357	2032	2040	survival	T052	C0038952
27513357	2042	2051	Silencing	T045	C0598496
27513357	2055	2076	lipoxygenase pathways	T044	C1157322
27513357	2078	2092	5-lipoxygenase	T044	C1151570
27513357	2097	2099	12	T044	C1151569
27513357	2102	2117	15-lipoxygenase	T044	C1324412
27513357	2130	2139	important	T080	C3898777
27513357	2140	2147	enzymes	T116,T126	C0014442
27513357	2152	2163	specialized	T077	C1704211
27513357	2164	2176	proresolving	T033	C0243095
27513357	2177	2191	lipid mediator	T123	C0599745
27513357	2192	2204	biosynthesis	T169	C0005572
27513357	2206	2214	resulted	T169	C1274040
27513357	2228	2239	therapeutic	T169	C0302350
27513357	2240	2247	benefit	T081	C0814225
27513357	2260	2285	mesenchymal stromal cells	T025	C3178844
27513357	2289	2304	carbon monoxide	T131,T197	C0007018
27513357	2328	2332	data	T078	C1511726
27513357	2360	2371	specialized	T077	C1704211
27513357	2372	2384	proresolving	T033	C0243095
27513357	2385	2400	lipid mediators	T123	C0599745
27513357	2401	2411	contribute	T052	C1880177
27513357	2415	2423	improved	T033	C0184511
27513357	2424	2448	mesenchymal stromal cell	T025	C3178844
27513357	2449	2457	efficacy	T080	C1280519
27513357	2463	2473	exposed to	T080	C0332157
27513357	2474	2489	carbon monoxide	T131,T197	C0007018
27513357	2507	2515	improved	T033	C0184511
27513357	2516	2536	therapeutic response	T201	C0521982
27513357	2537	2543	during	T079	C0347984
27513357	2544	2550	sepsis	T047	C0243026